Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated: May 06, 2026

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 258    

Filtered results: 258

Early Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial

Vaduganthan M., et al, JACC. 2026

Vaduganathan M, 08 04 2026

Estimated Glomerular Filtration Rate (eGFR) Slope, Chronic Kidney Disease (CKD) Progression and Pillars of Care in Diabetic Kidney Disease (DKD) Patients

Kushner P., et al, DOCC. 2026

Kushner P, 07 04 2026

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Neves JS., et al, DOM. 2026

Neves JS, 07 04 2026

Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies that Slow Kidney Disease Progression: Clinical Practice Implications

Cherny D., et al, MCP. 2026

Cherney D, 06 04 2026

Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach

Abramov D. et al, CRM. 2026

Abramov D, 06 04 2026

Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Chronic Kidney Disease and Type 2 Diabetes: A Pooled Analysis of FIDELIO-DKD and FIGARO-DKD Trials

Ostrominski J., et al, EHJ. 2026

Ostrominski J, 06 04 2026

Mineralocorticoid Receptor Antagonists: Efficacy and Safety in Chronic Kidney Disease

Mottl A. et al, DOM. 2026

Mottl A, 25 03 2026

Finerenone in Type 1 Diabetes and Chronic Kidney Disease

Heerspink H., et al., NEJM. 2026

Heerspink H, 20 03 2026

Utilization and Clinical Characteristics of Patients with Type 2 Diabetes and Chronic Kidney Disease Prescribed Finerenone in the United States

Kovesdy C., et al., JCTE. 2026

Kovesdy C, 20 03 2026

Finerenone Utilization for Chronic Kidney Disease and Diabetes: Multicenter Real-World Study in the United States

Lin W., et al, JACC. 2026

Lin W, 18 03 2026